Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism

American Journal of Nephrology

Volumn 29, Issue 3, 2009, Pages 230-236

  Shigematsu, Takashi ^a   Akizawa, Tadao ^b   Uchida, Eiji ^b   Tsukamoto, Yusuke ^d   Iwasaki, Manabu ^c   Koshikawa, Shouzo ^e  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SEIKEI UNIVERSITY   (Japan)

^d Kasukabe Shuwa Hospital   (Japan)

^e SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Bone disease; Calcium; Hyperparathyroidism; Osteodystrophy; Parathyroid hormone

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS;

ABDOMINAL DISCOMFORT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; DISEASE MARKER; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OSTEODYSTROPHY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; BONE AND BONES; BONE RESORPTION; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 51549117750     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156717     Document Type: Article

References (21)

1. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;56:S14-S19.
2. Nemeth EF, Steffey ME, Hammerland LG, et al: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998;95:4040-4045.
3. Nagano N: Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006;109:339-365.
4. Block GA, Martin KJ, de Francisco AL, et al: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-1525.
5. Goodman WG: Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 2003;18:1206-1210.
6. Lien YH, Silva AL, Whittman D: Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1232-1237.
7. Jean G, Chazot C, Charra B: 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007;68:63-64.
8. Japanese Society for Dialysis Therapy: An overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial 2007;11:411-441.
9. Fukagawa M, Yumita S, Akizawa T, et al: Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008;23:328-335.
10. Kazama JJ: Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathroidism. Ther Apher Dial Suppl 2007;11:S44-S47.
11. Urena P, Basile C, Grateau G, et al: Shortterm effects of parathyroidectomy on plasma biochemistry in chronic uremia. Kidney Int 1989;36:120-126.
12. Peretz AM, Dhaene MM, Drowart A, Kinnaert P, et al: Evolution of osteocalcin, alkaline phosphatase and parathyroid hormone after parathyroidectomy in patients receiving chronic maintenance hemodialysis. J Rheumatol 1992;19:411-415.
13. Charhon SA, Berland YF, Olmer MJ, et al: Effects of parathyroidectomy on bone formation and mineralization in hemodialyzed patients. Kidney Int 1985;27:426-435.
14. Brasier AR, Nussbaum SR: Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 1988;84:654-660.
15. Brown EM, MacLeod RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:239-297.
16. Antonsen JE, Sherrard DJ, Andress DL: A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 1998;53:223-227.
17. Goodman WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001;59:1187-1201.
18. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, et al: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14:575-83.
19. Messa P, Macário F, Yaqoob M, et al: The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. J Am Soc Nephrol 2008;3:36-45.
20. Ogata H, Koiwa F, Shishido K, Kinugasa E: Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ther Apher Dial 2005;9:11-15.
21. Chertow GM, Blumenthal S, Turner S, et al: Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D or its analogues with controlled PTH and elevated calcium phosphate. Clin J Am Soc Nephrol 2006;1:305-312.